Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Neuroendocrine Tumors 143Carcinoma, Neuroendocrine 56Thyroid Cancer, Papillary 54Pheochromocytoma 50Thyroid Neoplasms 41Paraganglioma 41Pituitary Neoplasms 37Adrenocortical Carcinoma 31Neoplasms 30Multiple Endocrine Neoplasia Type 1 29Gastro-enteropancreatic neuroendocrine tumor 29Thyroid Carcinoma, Anaplastic 23Small Cell Lung Carcinoma 21Lung Neoplasms 21Carcinoid Tumor 20Sarcoma 19Breast Neoplasms 19Neoplasm Metastasis 18Carcinoma, Non-Small-Cell Lung 18Adenoma, Islet Cell 18Melanoma 17Carcinoma, Hepatocellular 17Prostatic Neoplasms 15Pancreatic Neoplasms 15Ovarian Neoplasms 15Neuroblastoma 15Colorectal Neoplasms 15Carcinoma, Renal Cell 15Adrenal Gland Neoplasms 15Adenocarcinoma, Follicular 15

Interventions

trametinib 1selpercatinib 1pralsetinib 1lenvatinib 1larotrectinib 1entrectinib 1dabrafenib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Thyroid Cancer Patients Who Received Target Therapy × Endocrine × 1 year × Clear all
NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Fudan University

Phase 4 Recruiting
800 enrolled
EndocrineHead & Neck

Advanced Thyroid Cancer Patients Who Received Target Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡